Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time

Anaesthesia

Volumn 59, Issue 11, 2004, Pages 1100-1103

  Blaicher, A M ^a   Landsteiner, H T ^a   Zwerina, J ^a   Leitgeb, U ^a   Volf, I ^a   Hoerauf, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Analgesics: non steroidal, rofecoxib; Platelet functions tests

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; LORNOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; ARTICLE; AUTOANALYZER; BLEEDING TIME; BLOOD VESSEL INJURY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; NORMAL HUMAN; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; PERIOPERATIVE CARE; PIROXICAM; PLATELET FUNCTION TESTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 7244239301     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2004.03907.x     Document Type: Article

References (19)

1. Blaicher AM, Landsteiner HT, Al-Falaki O, et al. Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. Anesthesia and Analgesia 2004; 98: 1082-5.
2. Homoncik M, Malec M, Marsik C, et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clinical and Experimental Rheumatology 2003; 21: 229-31.
3. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). American Journal of Medicine 1999; 107: 11S-6S.
4. Furst DE. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors. American Journal of Medicine 1999; 107: 18S-22S; discussion S-6S.
5. Vane JR. Biomedicine. Back to an aspirin a day? Science 2002; 296: 474-5.
6. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Seminars in Thrombosis and Hemostasis 1998; 24: 195-202.
7. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer - PFA-100. Seminars in Thrombosis and Hemostasis 1995; 21 (Suppl. 2): 106-12.
8. Mandell BF. General tolerability and use of nonsteroidal anti-inflammatory drugs. American Journal of Medicine 1999; 107 72S-6S.
9. Reasbeck PG, Rice ML, Reasbeck JC. Double-blind controlled trial of indomethacin as an adjunct to narcotic analgesia after major abdominal surgery. Lancet 1999; 33: 498-501.
10. Lindgren U, HD. Diclofenac for pain after hip surgery. Acta Anaesthesiologica Scandinavica 1985; 56: 28-31.
11. Bricker SR, Savage ME, Hanning CD. Peri-operative blood loss and non-steroidal anti-inflammatory drugs: an investigation using diclofenac in patients undergoing transurethral resection of the prostate. European Journal of Anaesthesiology 1987; 4: 429-34.
12. Rorarius G, Baer GA, Metsa-Ketala T, et al. Effects of perioperatively administered diclofenac and indomethacin on blood loss, bleeding time and plasma prostanoids in man. European Journal of Anaesthesiology 1989; 6: 335-42.
13. Wierod FS, Frandsen NJ, Jacobsen JD, et al. Risk of haemorrhage from transurethral prostatectomy in acetylsalicylic acid and NSAID-treated patients. Scandinavian Journal of Urology and Nephrology 1998; 32: 120-2.
14. Belisle S, Hardy J-F. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Annals of Thoracic Surgery 1996; 62: 1908-17.
15. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochemical Pharmacology 2002; 63: 817-21.
16. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. New England Journal of Medicine 2000; 343: 1520-8.
17. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 272-7.
18. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539-41.
19. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-52.